ALSO NOTED: Gene Logic takes second look at Merck KGaA drugs; Zars mounts IPO;

> A subsidiary of Germany-based Merck KGaA has inked a deal to help reposition and develop several of Gene Logic's potential drugs. The candidates had been subject of previous clinical trials that were discontinued "for reasons other than safety." Release

> Lobbyists for Herceptin coverage in New Zealand presented a 27,000-signature petition to Parliament in support of the drug. The activists want NZ drug authority PHARMAC to fund 12 months of Herceptin treatment, instead of the 9 weeks that's currently covered. Report

> AspenBio Pharma will step onto the NASDAQ exchange Tuesday. The company got approval to list its stock, using the symbol APPY. Report

> Zars Pharma, a maker of topical pain relievers, is mounting an initial public offering of 5 million shares in hopes of raising up to $78 million for clinical testing of new product candidates. Report

And Finally... A breakthrough study suggests Huntington's might be treated with existing drugs. Researchers at the University of Leeds say they've identified a protein that keeps 57 genes from working properly in Huntington's patients--and cancer drugs may help destroy that protein. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?